Esters dipeptide

Spirapril (37) is a clinically active antihypertensive agent closely related structurally and mechanistically to enalapril. Various syntheses are reported with the synthesis of the substituted proline portion being the key to the methods. This is prepared fkim l-carbobenzyloxy-4-oxopro-line methyl ester (33) by reaction with ethanedithiol and catalytic tosic acid. The product (34) is deprotected with 20% HBr to methyl l,4-dithia-7-azospiro[4.4 nonane-8-carboxylate (35), Condensation of this with N-carbobenzyloxy-L-alanyl-N-hydroxysuccinate leads to the dipeptide ester which is deblocked to 36 by hydrolysis with NaOH and then treatment with 20% HBr. The conclusion of the synthesis of spirapril (37) follows with the standard reductive alkylation [11]. 

Saturation of the aromatic ring of pentopril analogues is also consistent with ACE inhibition as demonstrated by the oral activity of indolapril (23). The necessary heterocyclic component (21) can in principle be prepared by catalytic perhydrogenation (Rh/C, HOAc) of the corresponding indole. A single isomer predominates. The product is condensed by amide bond formation with the appropriate alanylhomophenylalanyl dipeptide ester 20 to give 22. Selective saponification to 23 could be accomplished by treatment with HCl gas. Use of the appropriate stereoisomers (prepared by resolution processes) produces chiral indolapril [8]. 

Figure 15 The reaction of Pd11 salts with two equivalents of dipeptide ester in methanol in the presence of NaOMe as base results in dianionic complexes, which can be isolated by precipitation with suitable cations.

The N,0-[Co(en)2(AA-AA OR)]3+ dipeptide ester complexes are formed rapidly (seconds to minutes) at room temperature on treating... 

Table VI lists a number of dipeptide ester complexes prepared via aminolysis in Me2SO and isolated using ion-exchange chromatography many others have been obtained from similar syntheses. Crystal structures are available for A-[Co(en)2((S)-Ala-CR)-Phe)]Br3 H20 (26), obtained from reaction of A-[Co(en)2((S)-AlaOMe]3+ with (i )-PheOMe and acid hydrolysis (Fig. 1), and for A-[Co(en)2((S)-Leu-(S)-Leu OMe)]Cl3 4H20 (24), A-[Co(en)2((S,fl)-Ala-(S)-ValOMe)](C104)3 (24), and /3-[Co(trien)(Gly-GlyOEt)](C104)3 H20 (10). These show considerable variation in chelate 0-Ci-C2-N dihedral angles (0-35°) (10) and it remains to be seen whether this property is important to epimerization (at C2) in these species.

Removal of the dipeptide ester from the Co(N)4 center is best achieved (1) by electrolytic reduction of aqueous solutions at an Hg electrode ( — 1.0 V vs S.C.E., pH 5, NaCl/HCl electrolyte) and with recovery by ion-exchange (1, 2, 25) or reversed-phase HPLC separation (24). In the latter cases the Co(III)-dipeptide ester was first converted to the Co(III)-dipeptide acid by overnight hydrolysis in 6 M... 

Janetka and Rich (78) have utilized the considerable stability of ruthenium-77-arene systems in the synthesis of cyclic tripeptides as analogs of the protease inhibitor K-13 (cf. 34, Scheme 28). Their approach involves the construction of linear tripeptide complexes (35) using diimide/HOBt coupling of [Ru(Cp)(Boc-p-Cl-PheOH)]PF6 (Cp = 775-C5H5) with the appropriate dipeptide ester. Cyclization of 35 affords the biphenyl ether 36, which on photolysis (350 nm) gives 34. 

Typical syntheses of Co(III)-amino acid, amino acid ester, and dipeptide ester chelates are described below. The NMR spectra of the isolated products were in accord with expectation. The procedures given here are generally applicable, except for that given for [Co(en)2((iS)-GluOBzl)]I2. If this method is used to coordinate amino acids that are only partially soluble in Me2SO, more forcing conditions (extended reaction times, 1-5 h, 50-60°C) may be required. Dipeptide ester complexes are not always as amenable as [Co(en)2 (Val-GlyOEt)]I3 to crystallization from water. 

Lehn and Sirlin found a very high degree of enantiomeric differentiation in the reaction of [327] with racemic dipeptide p-nitrophenyl esters [Gly-(DL)-Phe-OPNP]. Gly-(L)-Phe-OPNP reacts at approximately the same rate as the achiral Gly-Gly-OPNP, but the D-enantiomeric dipeptide ester is converted at a... 

Kinetic data for release of p-nitrophenol from amino acid and dipeptide ester salt substrates in the presence of the macrocyclic reagent [3271 ... 

FIGURE 6.1 Constitutional factors affecting the reactivity of functional groups. (A) The reactivity of W depends on the location of the residue. (B) The amino group of a dipeptide ester reacts with the ester carbonyl to form a cyclic dipeptide amino groups of other peptide esters do not react in this manner. (C, D) Reactions between residues of identical configuration do not occur at the same rates as reactions between residues of opposite configuration. 

FIGURE 6.24 The cis and trans forms of the amide bond of a dipeptide ester and cyclization of the compound to the piperazine-2,5-dione. The tendency to cyclize is greater when the carboxy-terminal residue is proline or an IV-methylamino acid. In these cases the predominating form is cis, which places the amino and ester groups closer together. 

Once it is part of a cyclic dipeptide, the prolyl residue becomes susceptible to enantiomerization by base (see Section 7.22). The implication of the tendency of dipeptide esters to form piperazine-2,5-diones is that their amino groups cannot be left unprotonated for any length of time. The problem arises during neutralization after acidolysis of a Boc-dipeptide ester and after removal of an Fmoc group from an Fmoc-dipeptide ester by piperidine or other secondary amine. The problem is so severe with proline that a synthesis involving deprotection of Fmoc-Lys(Z)-Pro-OBzl produced only the cyclic dipeptide and no linear tripeptide. The problem surfaces in solid-phase synthesis after incorporation of the second residue of a chain that is bound to the support by a benzyl-ester type linkage. There is also the added difficulty that hydroxymethyl groups are liberated, and they can be the source of other side reactions. 

The traditional method for preparing activated esters of A -protected dipeptides is combination of the A-protected amino acid with the amino acid ester (Figure 7.16). The latter is obtained by A-deprotection of the diprotected amino acid in an acidic milieu. Coupling is achievable using the carbodiimide, mixed-anhydride, and acyl-azide methods. Success with this approach indicates that the esterified residues react preferentially with the other derivatives and not among themselves. The chain cannot be extended to the protected tripeptide ester because the dipeptide ester cyclizes too... 

FIGURE 7.34 Decomposition of the symmetrical anhydride of A-methoxycarbonyl-valine (R1 = CH3) in basic media.2 (A) The anhydride is in equilibrium with the acid anion and the 2-alkoxy-5(4//)-oxazolone. (B) The anhydride undergoes intramolecular acyl transfer to the urethane nitrogen, producing thelV.AT-fcwmethoxycarbonyldipeptide. (A) and (B) are initiated by proton abstraction. Double insertion of glycine can be explained by aminolysis of the AA -diprotected peptide that is activated by conversion to anhydride Moc-Gly-(Moc)Gly-0-Gly-Moc by reaction with the oxazolone. (C) The A,A -diacylated peptide eventually cyclizes to the IV.AT-disubstituted hydantoin as it ejects methoxy anion or (D) releases methoxycarbonyl from the peptide bond leading to formation of the -substituted dipeptide ester. 

FIGURE 8.7 Synthesis of a protected tripeptide containing a 2-hydroxy-4-methoxybenzyl-protected peptide bond.38 (A) Acylation of the carboxy-terminal residue, (B) removal of both protecting groups, (C) O-acylation of the benzyl-protector by the symmetrical anhydride of the amino-terminal residue, and (D) migration of the protected amino-terminal residue from the oxygen atom to the amino group of the dipeptide ester. 

---